AOD-9604 + CJC-1295

▸ Overview

The AOD-9604 + CJC-1295 combination joins the specific lipolytic effect of AOD-9604 with the GHRH stimulus of CJC-1295. It is researched for body-composition protocols: AOD acts on fat tissue without growth effects; CJC stimulates physiological GH secretion.

▸ Mechanism of action

• AOD-9604 acts directly on adipose tissue via beta-3 adrenergic receptors; CJC-1295 acts on the GH/IGF-1 axis.
• AOD-9604 provides direct lipolysis without effects on IGF-1; CJC-1295 adds muscle anabolism through IGF-1.
• The combination allows simultaneously targeting fat (AOD) and preserving/building muscle (CJC-1295).
• CJC-1295 also enhances lipolysis through the GH axis, adding its effect to that of AOD-9604.
• A combination oriented toward body recomposition: simultaneous fat reduction + increased lean mass.

▸ Administration

• Both subcutaneous: can be injected together or separately.
• Individual reconstitution with bacteriostatic water.
• Storage: refrigerate at 2–8 °C.

▸ Timing

• Fasted in the morning for AOD-9604's lipolytic effect.
• CJC-1295 can also be dosed before sleep.
• At least 30–60 minutes of fasting before and after AOD-9604.

▸ Dosing & cycles

• Cycles: 8–12 weeks.
• AOD-9604 daily; CJC-1295 per protocol (DAC or non-DAC).
• No impact on blood glucose according to AOD-9604 studies.

▸ Combinations

• Researched in body-composition protocols alongside Tesamorelin.
• Compatible with recovery peptides in compound stacks.

▸ Disclaimer

▸ Products